Market Overview

Mixed Response on Infinity Pharma as Shares Plunge Amid Phase I Data

Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

In reports published on Monday, Wells Fargo analyst Matthew Andrews and Piper Jaffray analyst Ian Somaiya had mixed responses on Infinity Pharma (NASDAQ: INFI) CLL drug data.

Wells Fargo calls the data "Very Solid" as its Phase 1/2 data on IPI-145 in chronic lymphocytic leukemia (CLL) continued to demonstrate "competitive efficacy profile" and tolerable safety profile. In addition, Infinity is seen to have taken appropriate steps to address a few new infectious/respiratory side effects that may raise investor concerns in N-T. Andrews gave Infinity an Outperform rating with price target at $46.50.

Piper Jaffray calls data "disappointing" as IPI-145 in CLL may disappoint investors with lack of improvement in response rates even after longer treatment duration. Analyst Ian Somaiya reiterated an Overweight rating on Infinity with price target at $50.00.

Shares of Infinity Pharma were down more than 25 percent Monday and at the time of publication shares of Infinity Pharma traded around $19.41.

Latest Ratings for INFI

DateFirmActionFromTo
Nov 2014NomuraMaintainsNeutral
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Ian Somaiya Matthew Andrews Piper Jaffray Wells FargoAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters